Development and application of replication-incompetent HSV-1-based vectors

Gene Therapy

Volumn 12, Issue , 2005, Pages S98-S102

  Berto, E ^a   Bozac, A ^a   Marconi, P ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Cancer gene therapy; Herpes simplex virus; Neuronal gene delivery; Replication incompetent viral vectors; Vaccination

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE A; CILIARY NEUROTROPHIC FACTOR; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPES VACCINE; INTERLEUKIN 2; NERVE GROWTH FACTOR; OVALBUMIN; PLASMID DNA; THYMIDINE KINASE; TUMOR NECROSIS FACTOR; VIRUS DNA; VIRUS VECTOR;

BLADDER DISEASE; CANCER THERAPY; CHRONIC PAIN; CONFERENCE PAPER; CYTOTOXICITY; FEASIBILITY STUDY; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; HERPES; HERPES SIMPLEX VIRUS; HUMAN; LYSOSOME STORAGE DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SPINAL CORD INJURY; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ANIMALS; BIOTECHNOLOGY; GENE THERAPY; GENETIC VECTORS; HAPLORHINI; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOTHERAPY; LYSOSOMAL STORAGE DISEASES; MICE; MODELS, ANIMAL; NERVOUS SYSTEM DISEASES; VIRUS REPLICATION;

ANIMALIA; DNA VIRUSES; HERPES; HUMAN HERPESVIRUS 1; MURINAE; SIMIAE; SIMPLEXVIRUS;

EID: 27544462820     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302623     Document Type: Article

References (53)

1. Marconi P et al. Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci USA 1996; 93: 11319-11320.
2. Wu N, Watkins SC, Schaffer PA, DeLuca NA. Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22. J Virol 1996; 70: 6358-6369.
3. Hardwicke MA, Sandri-Goldin RM. The herpes simplex virus regulatory protein ICP27 contributes to the decrease in cellular mRNA levels during infection. J Virol 1994; 68: 4797-4810.
4. Hardy WR, Sandri-Goldin RM. Herpes simplex virus inhibits host cell splicing, and regulatory protein ICP27 is required for this effect. J Virol 1994; 68: 7790-7799.
5. Spencer CA, Dahmus ME, Rice SA. Repression of host RNA polymerase II transcription by herpes simplex virus type 1. J Virol 1997; 71: 2031-2040.
6. Everett RD. Trans activation of transcription by herpes virus products: requirement for two HSV-1 immediate-early polypeptides for maximum activity. EMBO J 1984; 3: 3135-3141.
7. Gelman IH, Silverstein S. Identification of immediate early genes from herpes simplex virus that transactivate the virus thymidine kinase gene. Proc Natl Acad Sci USA 1985; 82: 5265-5269.
8. York IA et al. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 1994; 77: 525-535.
9. DeLuca NA, McCarthy AM, Schaffer PA. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol 1985; 56: 558-570.
10. Krisky DM et al. Rapid method for construction of recombinant HSV gene transfer vectors. Gene Therapy 1997; 4: 1120-1125.
11. Johnson PA, Wang MJ, Friedmann T. Improved cell survival by the reduction of immediate-early gene expression in replication- defective mutants of herpes simplex virus type 1 but not by mutation of the virion host shutoff function. J Virol 1994; 68: 6347-6362.
12. Krisky DM et al. Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Therapy 1998; 5: 1517-1530.
13. Moriuchi S et al. HSV vector cytotoxicity is inversely correlated with effective TKlGCV suicide gene therapy of rat gliosarcoma. Gene Therapy 2000; 7: 1483-1490.
14. Samaniego LA, Neiderhiser L, DeLuca NA. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol 1998; 72: 3307-3320.
15. Marconi P et al. Replication-defective herpes simplex virus vectors for neurotrophic factor gene transfer in vitro and in vivo. Gene Therapy 1999; 6: 904-912.
16. Goins WF et al. A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats. J Virol 1994; 68: 2239-2252.
17. Samaniego LA, Wu N, DeLuca NA. The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J Virol 1997; 71: 4614-4625.
18. Kaplitt MG et al. Preproenkephalin promoter yields region- specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector. Proc Natl Acad Sci USA 1994; 91: 8979-8983.
19. Gage PJ, Sauer B, Levine M, Glorioso JC. A cell-free recombination system for site-specific integration of multigenic shuttle plasmids into the herpes simplex virus type 1 genome. J Virol 1992; 66: 5509-5515.
20. Evans C et al. Progress in development of herpes simplex virus gene vectors for treatment of rheumatoid arthritis. Adv Drug Deliv Rev 1997; 27: 41-57.
21. van Zijl M et al. Regeneration of herpesviruses from molecularly cloned subgenomic fragments. J Virol 1988; 62: 2191-2195.
22. Sathananthan B et al. Purification of herpes simplex virus type 1 by density gradient centrifugation and estimation of the sedimentation coefficient of the virion. Apmis 1997; 105: 238-246.
23. Szilagyi JF, Cunningham C. Identification and characterization of a novel non-infectious herpes simplex virus-related particle. J Gen Virol 1991; 72 (Part 3): 661-668.
24. Jiang C et al. Immobilized cobalt affinity chromatography provides a novel, efficient method for herpes simplex virus type 1 gene vector purification. J Virol 2004; 78: 8994-9006.
25. Ozuer A et al. Effect of genetic background and culture conditions on the production of herpesvirus-based gene therapy vectors. Biotechnol Bioeng 2002; 77: 685-692.
26. Goins WF et al. Delivery using herpes simplex virus: an overview. Methods Mol Biol 2004; 246: 257-299.
27. Goins WF et al. Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity. J Virol 1999; 73: 519-532.
28. Puskovic V et al. Prolonged biologically active transgene expression driven by HSV LAP2 in brain in vivo. Mol Ther 2004; 10: 67-75.
29. Berthomme H et al. Evidence for a bidirectional element located downstream from the herpes simplex virus type 1 latency- associated promoter that increases its activity during latency. J Virol 2000; 74: 3613-3622.
30. Palmer JA et al. Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system. J Virol 2000; 74: 5604-5618.
31. Burton EA, Glorioso JC, Fink DJ. Gene therapy progress and prospects: Parkinson's disease. Gene Therapy 2003; 10: 1721-1727.
32. Yamada M et al. Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degenera- tion of neurons in the substantia nigra in vivo. Proc Natl Acad Sci USA 1999; 96: 4078-4083.
33. Goss JR et al. Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Therapy 2001; 8: 551-556.
34. Liu J et al. Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain. Mol Ther 2004; 10: 57-66.
35. Chattopadhyay M et al. Protective effect of herpes simplex virusmediated neurotrophin gene transfer in cisplatin neuropathy. Brain 2004; 127: 929-939.
36. Lanzi G, Ottolini A. Classification of neuromuscular diseases. Monaldi Arch Chest Dis 1993; 48: 62-64.
37. Korsching S. The neurotrophic factor concept: a reexamination. J Neurosci 1993; 13: 2739-2748.
38. Marconi P et al. Effects of defective herpes simplex vectors expressing neurotrophic factors on the proliferation and differentiation of nervous cells in vivo. Gene Therapy 2005; 12: 559-569.
39. Farrell HE et al. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J Virol 1994; 68: 927-932.
40. Morrison LA, Knipe DM. Immunization with replication- defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J Virol 1994; 68: 689-696.
41. Nguyen LH, Knipe DM, Finberg RW. Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J Virol 1992; 66: 7067-7072.
42. Murphy CG et al. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol 2000; 74: 7745-7754.
43. Lauterbach H et al. Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1. J Virol 2004; 78: 4020-4028.
44. Kuklin NA et al. Modulation of mucosal and systemic immunity by enteric administration of nonreplicating herpes simplex virus expressing cytokines. Virology 1998; 240: 245-253.
45. Brockman MA, Knipe DM. Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity. J Virol 2002; 76: 3678-3687.
46. Burton EA, Glorioso JC. Multi-modal combination gene therapy for malignant glioma using replication-defective HSV vectors. Drug Discov Today 2001; 6: 347-356.
47. Wolfe D et al. Safety and biodistribution studies of an HSV multigene vector following intracranial delivery to non-human primates. Gene Therapy 2004; 11: 1675-1684.
48. Niranjan A et al. Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. Mol Ther 2000; 2: 114-120.
49. Niranjan A et al. Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery. Mol Ther 2003; 8: 530-542.
50. Marconi P et al. Connexin 43-enhanced suicide gene therapy using herpesviral vectors. Mol Ther 2000; 1: 71-81.
51. Raffaella R et al. The interferon-inducible IFI16 gene inhibits tube morphogenesis and proliferation of primary, but not HPV16 E6l E7-immortalized human endothelial cells. Exp Cell Res 2004; 293: 331-345.
52. Sasaki K et al. Gene therapy using replication-defective herpes simplex virus vectors expressing nerve growth factor in a rat model of diabetic cystopathy. Diabetes 2004; 53: 2723-2730.
53. Fradette J et al. HSV vector-mediated transduction and GDNF secretion from adipose cells. Gene Therapy 2005; 12: 48-58.